NCT05195541View on ClinicalTrials.gov

A Clinical Study to Evaluate the Safety, Pharmacokinetic Profile and Efficacy of CU-20401

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

February 27, 2022

Primary Completion Date

December 30, 2022

Study Completion Date

December 30, 2022

Conditions
Safety
Interventions
DRUG

CU-20401

Subcutaneous injection in the subcutaneous fat area，0.2ml

Trial Locations (1)

200082

Shanghai Changhai Hospital, Shanghai

Sponsors
All Listed Sponsors
lead

Cutia Therapeutics（Wuxi）Co.,Ltd

INDUSTRY